Solventum Corporation(SOLV) - 2025 Q2 - Earnings Call Presentation

Q2 FY25 Financial Performance - Solventum's total sales reached $2161 million, with a reported year-over-year increase of 3.9% and an organic growth of 2.8%[12] - The company's GAAP operating margin was 9.9%, while the non-GAAP operating margin was significantly higher at 21.9%[13] - GAAP EPS stood at $0.51, and non-GAAP EPS was $1.69[13] - Cash from operations amounted to $169 million, while free cash flow was $59 million[13] Segment Performance - MedSurg segment sales were $1218 million, showing a reported increase of 4.8% and an organic growth of 3.9%[12, 15] - Dental Solutions segment achieved $338 million in sales, with a reported growth of 2.3% and an organic growth of 0.7%[12, 19] - Health Information Systems segment reported sales of $339 million, reflecting a 3.4% increase, with organic growth at 3.2%[12, 23] - Purification & Filtration segment's sales were $252 million, with a reported increase of 5.4% and an organic growth of 3.1%[12, 26] FY2025 Guidance - The company raised its organic sales growth guidance to a range of 2.5% to 3.5%, excluding an approximate 50bps impact from SKU exits[29] - Adjusted EPS guidance was increased to $5.80 - $5.95[30]